Saturday 17 October 2026 Export AXGN’s income statement to Excel — free account

AxoGen, Inc.

AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.1%, EPS fell 400.0%, free cash flow fell 17.4% and total debt fell 72.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

34.62 1.01 −2.83%

Follow AXGN

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: −110×
Dividend yield: —
F-score: 5/9
Altman Z: 9.23
Beneish M: −2.73
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 18.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	13	—	—	1	—	6	—	—	3	1	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2,090.00

Revenue 251.17

Net Income (33.55)

Free Cash Flow 6.51

Net Debt (95.32)

Current Ratio 6.60

Debt/Equity 0.07

P/E ratio 0.00

Fwd P/E (110.00)

P/S ratio 7.35

P/B ratio 7.21

Past 5Y EPS Growth —

This Y EPS Growth 56.52%

Next Y EPS Growth 50.87%

Next Y revenue growth 26.82%

Next 5Y EPS Growth 50.64%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 70.33%

10-year low 10-year high

P/B against its own 10 years 60.82%

10-year low 10-year high

EV/Sales against its own 10 years 68.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	37	39	46	113
Receivables	25	24	26	34
Inventory	23	33	42	47
Other	—	—	—	—
	88	99	120	200

	2023	2024	2025	Q'26
Payables	29	29	21	28
ST’ Debt	—	2	2	—
Other	—	—	—	—
	30	31	24	30

Compound Annual Growth %

	10y	5y	3y
Sales	23.48%	14.93%	17.57%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	31.72%	0.91%	8.46%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	61	70	—	—	—
’25	49	57	60	60	225
’24	41	48	49	49	187
’23	37	38	41	43	159
’22	31	34	37	36	139
’21	31	34	31	32	127
’20	24	22	33	32	112

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	7	—	—	—
’25	(13)	8	3	3	1
’24	(12)	4	4	9	5
’23	(7)	0	2	0	(6)
’22	(11)	(6)	(1)	1	(16)
’21	(11)	(1)	0	(2)	(13)
’20	(8)	(7)	3	3	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	5	—	—	—
’25	(14)	7	1	1	(5)
’24	(14)	3	3	8	0
’23	(12)	(4)	(2)	(2)	(21)
’22	(17)	(10)	(5)	(5)	(37)
’21	(14)	(9)	(10)	(9)	(42)
’20	(13)	(15)	(3)	0	(32)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.38)	(0.03)	—	—	—
’25	(0.08)	0.01	0.01	(0.28)	(0.34)
’24	(0.15)	(0.04)	(0.04)	0.01	(0.23)
’23	(0.17)	(0.16)	(0.10)	(0.09)	(0.51)
’22	(0.27)	(0.18)	(0.10)	(0.13)	(0.69)
’21	(0.16)	(0.19)	(0.17)	(0.13)	(0.65)
’20	(0.21)	(0.20)	(0.04)	(0.15)	(0.60)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.52	8.75	16.52	10.91	7.16	8.48	6.87	3.45	5.55	9.22	Analyst estimates 2026–2028 Powerpack
	High	9.88	28.90	56.85	25.84	18.43	23.94	13.66	11.32	17.23	34.24
People
People	Employees	146	199	297	394	368	451	396	428	452	622
	Revenue/emp, $m	0.28	0.30	0.28	0.27	0.31	0.28	0.35	0.37	0.41	0.36
Income, $m
Income, $m	Revenue	41	60	84	107	112	127	139	159	187	225
	Gross margin, %	84.27	84.59	84.60	83.74	80.78	81.99	78.51	76.64	75.79	74.31
	EBT	(14)	(10)	(22)	(29)	(24)	(27)	(29)	(22)	(10)	(16)
	EBT margin, %	(35.06)	(17.29)	(26.68)	(27.30)	(21.18)	(21.19)	(20.89)	(13.66)	(5.32)	(6.97)
	Net income	(14)	(10)	(22)	(29)	(24)	(27)	(29)	(22)	(10)	(16)
	Depreciation	1	1	1	3	4	6	6	6	9	9
Per share, $
Per share, $	Revenue	1.34	1.81	2.26	2.72	2.81	3.09	3.29	3.71	4.23	4.89
	Earnings	(0.47)	(0.31)	(0.60)	(0.74)	(0.60)	(0.65)	(0.69)	(0.51)	(0.23)	(0.34)
	Cash flow	(0.37)	(0.28)	(0.48)	(0.51)	(0.24)	(0.33)	(0.38)	(0.13)	0.10	0.02
	Capex	(0.04)	(0.04)	(0.18)	(0.13)	(0.57)	(0.69)	(0.50)	(0.35)	(0.10)	(0.12)
	Free cash flow	(0.40)	(0.32)	(0.66)	(0.64)	(0.81)	(1.01)	(0.89)	(0.48)	0.00	(0.10)
	Book value	0.49	0.76	3.96	3.37	3.08	2.73	2.40	2.23	2.35	2.80
	Shares, m	31	33	37	39	40	41	42	43	44	46
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	6.65	15.41	9.04	6.58	6.37	3.03	3.00	1.86	3.89	6.69
	P/B	18.31	36.99	5.16	5.31	5.81	3.43	4.12	3.10	7.02	11.70
	EV/Sales	6.51	15.22	7.58	5.65	5.86	2.85	3.09	2.06	4.05	6.79
	EV/FCF	(21.59)	(87.32)	(26.00)	(24.02)	(20.43)	(8.69)	(11.47)	(15.90)	68,961.14	(319.81)
Cash, $m
Cash, $m	Operating cash flow	(11)	(9)	(18)	(20)	(10)	(13)	(16)	(6)	5	1
	Capex	(1)	(1)	(7)	(5)	(23)	(28)	(21)	(15)	(5)	(6)
	Free cash flow	(12)	(11)	(24)	(25)	(32)	(42)	(37)	(21)	0	(5)
Balance, $m
Balance, $m	Working capital	33	42	138	114	122	103	74	58	69	97
	Total debt	24	25	0	3	54	67	67	68	69	68
	Net debt	(6)	(12)	(122)	(99)	(57)	(23)	12	31	29	22
	Shareholders’ equity	15	25	147	132	123	113	101	96	104	129
Returns, %
Returns, %	ROA	(34.70)	(19.85)	(20.45)	(18.51)	(13.36)	(13.18)	(14.35)	(11.07)	(4.98)	(7.38)
	ROIC	(55.12)	(37.30)	(52.30)	(59.53)	(21.92)	(17.72)	(16.37)	(10.61)	(1.54)	(3.25)
	ROE	(124.68)	(52.09)	(26.02)	(20.88)	(18.63)	(22.90)	(27.11)	(22.08)	(9.99)	(13.49)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NEOG Neogen Corporation	$2.7B	— (loss-making)	— (loss-making)	+6.51% (above 0%: growing)	n/m	+135.75% (above 0%: growing)	47.35%	(0.81%)	Compare
TMDX TransMedics Group, Inc.	$2.7B	16.0×	34.1×	+20.70% (above 0%: growing)	−59.22% (below 0%: shrinking)	−87.62% (below 0%: shrinking)	59.59%	12.50%	Compare
UFPT UFP Technologies, Inc.	$2.3B	31.2×	23.6×	+15.07% (above 0%: growing)	+20.63% (above 0%: growing)	−35.77% (below 0%: shrinking)	29.27%	16.15%	Compare
BFLY Butterfly Network, Inc.	$2.1B	— (loss-making)	— (loss-making)	+39.47% (above 0%: growing)	n/m	−113.85% (below 0%: shrinking)	71.41%	(41.90%)	Compare
AXGN AxoGen, Inc.	$2.1B	— (loss-making)	— (loss-making)	+23.06% (above 0%: growing)	n/m	−17.36% (below 0%: shrinking)	72.67%	(3.09%)
INSP Inspire Medical Systems, Inc.	$2.0B	14.8×	93.5×	−7.60% (below 0%: shrinking)	n/m	+322.84% (above 0%: growing)	85.48%	(0.26%)	Compare
ESTA Establishment Labs Holdings Inc.	$1.8B	— (loss-making)	— (loss-making)	+31.66% (above 0%: growing)	n/m	+2.75% (above 0%: growing)	70.64%	(6.35%)	Compare
ATEC Alphatec Holdings, Inc.	$1.7B	— (loss-making)	— (loss-making)	+15.07% (above 0%: growing)	n/m	−146.87% (below 0%: shrinking)	72.17%	(0.89%)	Compare
NVCR NovoCure Limited	$1.7B	— (loss-making)	— (loss-making)	+15.60% (above 0%: growing)	n/m	+105.68% (above 0%: growing)	77.61%	(5.75%)	Compare
Median of peers	$2.1B	16.0×	34.1×	+15.34%	—	−16.51%	71.03%	(0.85%)

All 149 Medical Devices stocks →

AxoGen, Inc. (AXGN) key facts

Strength: AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
AxoGen, Inc. (AXGN) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AXGN traded at $34.62, a market capitalization of $2.1 billion.
Return on equity was −13.5% and debt-to-equity 0.07.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 9.23 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.